Compare Recursion Pharmaceuticals Inc (RXRX) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Verisign, Inc. — how do they compare? Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B), while Verisign, Inc. trades at $284.45 (market cap $26.00B). The key difference: Verisign, Inc. is far larger — about 14.4× Recursion Pharmaceuticals Inc's market cap, and Verisign, Inc. pays a 1.13% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | VRSN | |
|---|---|---|
Market Cap | $1.81B | $26.00B |
Sector | Health | Technology |
52-Week High | $6.79 | $310.00 |
52-Week Low | $2.84 | $211.49 |
Enterprise Value | $1.33B | $27.31B |
Dividend Yield | — | 1.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
VeriSign (VRSN) trades at $283.56, down 3.33% today, amid mixed quarterly earnings but maintains a bullish technical trend with strong moving averages. The company reported Q2 2026 revenue of $435 million, up 6% year-over-year, with EPS of $2.38 beating estimates. Recent delegation of the .web domain and AI-driven registration growth support a positive outlook, though valuation ratios like P/E of 31.23 suggest a premium.
The stock offers upside to the consensus price target of $320, driven by domain growth and pricing power, but risks include high debt levels and reliance on .com/.net contracts. Analyst sentiment is bullish with 60% buy ratings, yet investors should monitor execution on guidance and contract renewals for sustained momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
